onr:"swepub:oai:DiVA.org:umu-162840"
Search: onr:"swepub:oai:DiVA.org:umu-162840" > Safe Use of Immune ...
- 1 of 1
- Previous record
- Next record
- To hitlist
Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer : The European Association of Urology Position in 2019
- Grimm, Marc-Oliver (author)
- Bex, Axel (author)
- De Santis, Maria (author)
- show more...
- Catto, James W. F. (author)
- Rouprêt, Morgan (author)
- Hussain, Syed A. (author)
- Bellmunt, Joaquim (author)
- Powles, Tom (author)
- Wirth, Manfred (author)
- Van Poppel, Hendrik (author)
- show less...
- (creator_code:org_t)
- Elsevier, 2019
- 2019
- English.
- In: European Urology. - : Elsevier. - 0302-2838 .- 1873-7560. ; 76:3, s. 368-380
- Research review (peer-reviewed)
Abstract
Subject headings
Close
- Immune checkpoint inhibitors (ICIs) are now used routinely to treat advanced or metastatic urothelial and renal cell carcinoma, among other cancers. Furthermore, multiple trials are currently exploring their role in adjuvant, neoadjuvant, and noninvasive (eg, high-grade non-muscle-invasive bladder cancer) settings. Consequently, urologists are increasingly confronted with patients who are on, have recently received, or will be treated with ICI therapy. The care of these patients is likely to be shared between urologists and medical oncologists, with additional occasional support of other medical specialties. Therefore, it is important that urologists have good knowledge of immune-related side effects. Here, we provide advice on prevention, early diagnosis, and clinical management of the most relevant toxicities to strengthen urologists' insight and, thus, role in the multidisciplinary management in the new immunotherapy era. Patient summary: Immune therapy is a common treatment for many patients with advanced cancer. We describe common side effects of this treatment, and advise how they are best prevented and managed.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
Keyword
- Immunotherapy
- Immune checkpoint inhibitors
- Immune related
- Adverse events
- Atezolizumab
- Avelumab
- Durvalumab
- Ipilimumab
- Nivolumab
- Pembrolizumab
Publication and Content Type
- ref (subject category)
- for (subject category)
Find in a library
- European Urology (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Grimm, Marc-Oliv ...
- Bex, Axel
- De Santis, Maria
- Ljungberg, Börje ...
- Catto, James W. ...
- Rouprêt, Morgan
- show more...
- Hussain, Syed A.
- Bellmunt, Joaqui ...
- Powles, Tom
- Wirth, Manfred
- Van Poppel, Hend ...
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Urology and Neph ...
- Articles in the publication
- European Urology
- By the university
- Umeå University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
